Seeking Alpha
View as an RSS Feed

BlackbirdAnalytics  

View BlackbirdAnalytics' Comments BY TICKER:
Latest  |  Highest rated
  • Straight Talk From Allon Therapeutics CEO Gordon McCauley [View article]
    Read my original article on Allon and get very familiar with primary endpoints for PSP. The previous studies and pre-clinical data, should be devoured.

    Just remember, $npcuf.pk market opportunity is greater that $srpt. See how $srpt was trading under a $1.00 a few months ago and data cured all ills.....to win it you have to be in it.....Good luck!
    Oct 5, 2012. 09:31 AM | Likes Like |Link to Comment
  • Straight Talk From Allon Therapeutics CEO Gordon McCauley [View article]
    Thanks for posting it. VERY Important difference

    12 weeks for neurodeneragitive study can be nothing BUT SAFETY study.

    Anyone drawing conclusion after 12 weeks doesn't understand brain disorders.

    Safety was superb hence Allon went for highest dose.
    Oct 5, 2012. 08:42 AM | Likes Like |Link to Comment
  • Straight Talk From Allon Therapeutics CEO Gordon McCauley [View article]
    Thanks for the compliment. I agree it would trade much higher on NASDAQ. Not sure $5.00, thats too optimistic :-) Most definitely in $1.50-$2.50 range.

    As CEO said, data cures all ills and you have to be "in it, to win it."
    Oct 4, 2012. 07:47 AM | Likes Like |Link to Comment
COMMENTS STATS
33 Comments
11 Likes